It’s currently a very busy & successful time for Avacta (AVCT ) – a leading life sciences firm developing innovative, new cancer treatments & powerful diagnostics.
Hence, I was delighted today to catchup with CEO Alastair Smith, who took me through:
(00:00) Progress of AVA6000 clinical trial wrt safety, dosing regimes, efficacy and ultimate usage.
(10:25) Update on #AVCT’s preCISION enabled proteasome inhibitor AVA3996.
The information, investment views and recommendations in this article are provided for general information purposes only. Nothing in this article should be construed as a solicitation to buy or sell any financial product relating to any companies under discussion or to engage in or refrain from doing so or engaging in any other transaction. Any opinions or comments are made to the best of the knowledge and belief of the writer but no responsibility is accepted for actions based on such opinions or comments. Vox Markets may receive payment from companies mentioned for enhanced profiling or publication presence. The writer may or may not hold investments in the companies under discussion.
